DK3455625T3 - PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY - Google Patents

PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY Download PDF

Info

Publication number
DK3455625T3
DK3455625T3 DK17726208.6T DK17726208T DK3455625T3 DK 3455625 T3 DK3455625 T3 DK 3455625T3 DK 17726208 T DK17726208 T DK 17726208T DK 3455625 T3 DK3455625 T3 DK 3455625T3
Authority
DK
Denmark
Prior art keywords
immunteraphy
antenges
neo
predicting
applicability
Prior art date
Application number
DK17726208.6T
Other languages
Danish (da)
Inventor
Ugur Sahin
Barbara Schrörs
Sebastian Boegel
Martin Löwer
Mathias Vormehr
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Application granted granted Critical
Publication of DK3455625T3 publication Critical patent/DK3455625T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4712Muscle proteins, e.g. myosin, actin, protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK17726208.6T 2016-05-13 2017-05-10 PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY DK3455625T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/060897 WO2017194170A1 (en) 2016-05-13 2016-05-13 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
PCT/EP2017/061196 WO2017194610A1 (en) 2016-05-13 2017-05-10 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Publications (1)

Publication Number Publication Date
DK3455625T3 true DK3455625T3 (en) 2020-10-26

Family

ID=55971007

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17726208.6T DK3455625T3 (en) 2016-05-13 2017-05-10 PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY
DK20193183.9T DK3792628T3 (en) 2016-05-13 2017-05-10 METHODS FOR PREDICTING THE USEFULNESS OF NEOANTIGENS FOR IMMUNE THERAPY

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20193183.9T DK3792628T3 (en) 2016-05-13 2017-05-10 METHODS FOR PREDICTING THE USEFULNESS OF NEOANTIGENS FOR IMMUNE THERAPY

Country Status (26)

Country Link
US (1) US20190178871A1 (en)
EP (2) EP3455625B1 (en)
JP (2) JP2019520554A (en)
KR (2) KR102358620B1 (en)
CN (1) CN109073637A (en)
AU (2) AU2017264546B2 (en)
BR (1) BR112018073221A2 (en)
CA (1) CA3022654A1 (en)
CY (1) CY1123520T1 (en)
DK (2) DK3455625T3 (en)
ES (1) ES2826480T3 (en)
FI (1) FI3792628T3 (en)
HR (1) HRP20201671T1 (en)
HU (1) HUE052240T2 (en)
IL (2) IL300841A (en)
LT (2) LT3792628T (en)
MA (1) MA43794B1 (en)
MD (1) MD3455625T2 (en)
MX (2) MX2018013081A (en)
PL (1) PL3455625T3 (en)
PT (1) PT3455625T (en)
RS (1) RS61071B1 (en)
SG (1) SG11201808495SA (en)
SI (1) SI3455625T1 (en)
WO (2) WO2017194170A1 (en)
ZA (1) ZA201805809B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3754022A4 (en) * 2018-02-15 2021-09-29 National University Corporation Asahikawa Medical University Cancer antigen peptide
CN109021062B (en) * 2018-08-06 2021-08-20 倍而达药业(苏州)有限公司 Screening method of tumor neoantigen
CN111621564B (en) * 2019-02-28 2022-03-25 武汉大学 Method for identifying effective tumor neoantigen
CN110534156B (en) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 Method and system for extracting immunotherapy new antigen
CN111487399B (en) * 2020-03-26 2021-09-17 湖南师范大学 Application of protein molecular marker in research on fish germ cell development
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (en) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD
WO2006105255A2 (en) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
JP2009273377A (en) * 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Method for selecting candidate peptide presented on surface of cancer cell following binding to mhc class i molecule
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
SI2172211T1 (en) * 2008-10-01 2015-03-31 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
CA2778707A1 (en) * 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
WO2012164004A1 (en) * 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel antigen peptide and uses thereof

Also Published As

Publication number Publication date
CA3022654A1 (en) 2017-11-16
KR102358620B1 (en) 2022-02-07
IL262680B1 (en) 2023-04-01
RS61071B1 (en) 2020-12-31
US20190178871A1 (en) 2019-06-13
PL3455625T3 (en) 2021-01-25
AU2022209286A1 (en) 2022-08-25
KR20190008218A (en) 2019-01-23
EP3792628A2 (en) 2021-03-17
RU2018137721A (en) 2020-06-15
CY1123520T1 (en) 2022-03-24
RU2018137721A3 (en) 2020-08-25
LT3455625T (en) 2021-01-11
IL262680B2 (en) 2023-08-01
WO2017194610A1 (en) 2017-11-16
BR112018073221A2 (en) 2019-02-19
SG11201808495SA (en) 2018-10-30
ZA201805809B (en) 2020-12-23
ES2826480T3 (en) 2021-05-18
AU2017264546B2 (en) 2022-04-28
DK3792628T3 (en) 2024-06-17
IL262680A (en) 2018-12-31
MA43794A (en) 2019-03-20
LT3792628T (en) 2024-06-25
JP2022081492A (en) 2022-05-31
JP2019520554A (en) 2019-07-18
HRP20201671T1 (en) 2021-03-05
EP3792628A3 (en) 2021-05-19
CN109073637A (en) 2018-12-21
MD3455625T2 (en) 2020-12-31
HUE052240T2 (en) 2021-04-28
PT3455625T (en) 2020-10-22
EP3792628B1 (en) 2024-04-24
SI3455625T1 (en) 2021-01-29
IL300841A (en) 2023-04-01
AU2017264546A1 (en) 2018-10-18
FI3792628T3 (en) 2024-06-07
EP3455625A1 (en) 2019-03-20
KR20220020993A (en) 2022-02-21
MX2018013081A (en) 2019-01-24
MX2022007902A (en) 2022-07-21
MA43794B1 (en) 2020-12-31
WO2017194170A1 (en) 2017-11-16
EP3455625B1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
DK3512850T3 (en) INHIBITORS OF THE MENIN-MLL INTERACTION
DK3468966T3 (en) INHIBITORS OF THE MENIN-MLL INTERACTION
DK3192902T3 (en) PROCEDURE FOR THE MANUFACTURE OF GRAPHENCY VISCOSEFIBREES
DK3300500T3 (en) TRIAZOLAGONISTS OF THE APJ RECEPTOR
DK3096741T3 (en) PROCEDURE FOR THE PREPARATION OF HYBRIDOSOMES
DK3512959T3 (en) Methods for performing multiplex PCR
DK3325443T3 (en) PROCEDURE FOR THE MANUFACTURE OF PRIDOPIDINE
DK3466432T3 (en) PROCEDURES FOR THE TREATMENT OF PULMONAL NON-TUBERCULOSE MICOBACTERIAL INFECTIONS
DK3286311T3 (en) PROCEDURE FOR TREATING MALIGNITIES
DK3473783T3 (en) PROCEDURE FOR MAKING FLOOR TILES
DK3072835T3 (en) PROCEDURE FOR PROCEDURE
DK3556775T3 (en) ANTI-LAG-3 ANTIBODIES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES
DK3174858T3 (en) PROCEDURE FOR THE PREPARATION OF PYRAZOLS
DK3294700T3 (en) PROCEDURE FOR PREPARING LIMONEN-4 OL
DK3198035T3 (en) Methods for predicting drug response
DK3317400T3 (en) PROCEDURE FOR CRYO-PRESERVATION OF TUMOR-INFILRATING LYMPOCYTS
DK3317394T3 (en) DEVICE FOR PROPAGATION OF MICRO TISSUES
DK3940352T3 (en) PROCEDURE FOR DIAGNOSING WEIGHTS
DK3126373T3 (en) PROCEDURE FOR MANUFACTURING AMG 416
DK3344805T3 (en) PROCEDURE FOR SELECTING APTAMER FOR UNBINDED OBJECTIVES
DK3455625T3 (en) PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY
DK3186244T3 (en) DIOXOLANALOGS OF URIDINE FOR THE CANCER OF CANCER
DK3507408T3 (en) PROCEDURE FOR MAKING THE NONWOVEN
DK3233813T3 (en) PROCEDURES FOR THE PREPARATION OF OXATHIAZINE-LIKE COMPOUNDS
DK3280408T3 (en) PROCEDURE FOR THE PREPARATION OF DICYCLOPLATIN